1. Is Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) is a average quality company.
2. Is Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) undervalued or overvalued?
No data found
3. Is Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) a good buy now?
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||11.5%||10.2%||15.5%||9.5%||6%||7.7%||8.6%||10.4%||7.2%||8.8%||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||30.5%||15.8%||-15.2%||19.3%||10.1%||4.6%||-2.3%||4%||3.7%||-|
|Adj EPS ⓘ||3.8||3.7||6.3||4.3||2.4||3.2||4.1||5.3||3.3||5.2||4.1|
|YoY Gr. Rt. %||-||-1.9%||71.5%||-32.7%||-43.2%||31%||30.3%||28.3%||-38.1%||59.2%||-|
|BVPS (₹) ⓘ||18.5||28.3||34||37.8||39.6||41.6||44.8||49.3||51.7||56.4||295.5|
|Adj Net Profit ⓘ||54.2||58.9||102||68.8||39.1||51.1||66.7||85.6||53||84.2||66|
|Cash Flow from Ops. ⓘ||21.2||42.5||90.8||110||118||250||28.3||126||14.5||125||-|
|Debt/CF from Ops. ⓘ||14.1||6.2||3.2||4||4.8||2||18.5||4.2||43.4||5||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||3.7%||16.6%||8.1%||59.2%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||24.6||16.3||20.3||11.8||6.2||7.8||9.5||11.2||6.5||9.6||2.3|
|Op. Profit Mgn % ⓘ||25.7||25.6||36.1||33.3||24||33.4||36||37.2||30.1||33.5||32.5|
|Net Profit Mgn % ⓘ||19.7||16.4||24.6||19.5||9.3||11||13.8||18.1||10.8||16.5||15.7|
|Debt to Equity ⓘ||1.1||0.6||0.5||0.7||0.9||0.7||0.7||0.7||0.8||0.7||-|
|Working Cap Days ⓘ||325||307||270||347||417||436||406||467||564||638||0|
|Cash Conv. Cycle ⓘ||183||168||133||101||79||61||53||50||85||91||0|
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Net Profit has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
|TTM EPS (₹)||4.1||10|
|TTM Sales (₹ Cr.)||417||1,609|
|BVPS (₹.) ⓘ||295.5||297.9|
|Reserves (₹ Cr.) ⓘ||4,737||4,776|
|From the Market|
|52 Week Low / High (₹)||278.10 / 304.30|
|All Time Low / High (₹)||16.25 / 346.25|
|Market Cap (₹ Cr.)||4,859|
|Equity (₹ Cr.)||32.3|
|Face Value (₹)||2|
|Industry PE ⓘ||37.3|
Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and earned the status of the â€œQuat Companyâ€. In the period of 10 years the production capacity was increased from 10MT per annum to 1500 Mt per annum.
In the year 1995, the company entered into a joint ventured with SchÃ¼tz & Co,
Headquartered at Ahmedabad, the company owns three manufacturing units, two located at Bavla and one at Naroda. Presently the company is manufactures a range of Bulk APIs, Intermediates, Specialties and Quats. The company has representative office located at
DPCL is engaged in the manufacture of active pharmaceutical ingredients (APIs) intermediates. The Company operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quats and specialty chemicals. It provides a range of products to the global market, including a range of reagents, specialty chemicals, APIs and their intermediates.
Dishman Specialty Chemicals, which manufactures Phase Transfer Catalysts;
Dishman Vitamins and Chemicals, which manufactures Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and laolin related products for pharmaceutical, cosmetic and related markets,
Dishman Disinfectants, which manufactures antiseptic and disinfectant formulations.
The products manufactured by the company include bulk drugs, phase transfer catalyst and fine chemicals